Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPL-108 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Splash Pharmaceuticals
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Subcutaneous (SPL-108), Intravenous (paclitaxel)
01
Overview
SPL-108 + paclitaxel is a **combination therapy** consisting of SPL-108, a targeted small molecule inhibitor, and paclitaxel, a standard cytotoxic chemotherapeutic agent. SPL-108 inhibits CD44-mediated induction of multidrug resistance, specifically reducing P-glycoprotein (ABCB1) expression and thereby reversing resistance to agents like paclitaxel and platinum drugs. Paclitaxel disrupts microtubule function, leading to cell cycle arrest and apoptosis, especially in rapidly dividing cancer cells. The combination is developed primarily to treat **platinum-resistant, CD44+ advanced ovarian epithelial cancers**, with early-phase trials suggesting favorable safety and antitumor activity. SPL-108 is supplied as a subcutaneous injection, and paclitaxel is administered intravenously[1][2][3][4][5].
- Brand names
- SPL-108 + paclitaxel
- Other names
- SPL-108/paclitaxelSPL-108 and paclitaxelSPL108 and paclitaxelSPL 108 and paclitaxel
02
Targets
CD44 (CD44 antigen)TUBB (Tubulin (alpha and beta subunits))ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on SPL-108 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPL-108 + paclitaxel.